Yukinari Kato
Professor
Department Antibody Drug Development
Tohoku University
Japan
Biography
Dr. Yukinari Kato is Professor at Antibody Drug Development, Tohoku University. His research theme are Development of innovative next generation cancer-specific monoclonal antibodies and clinical application. Protein expression and antibody production using antibody-engineering technologies. Development of therapeutic devices using tumor-specific antibodies.
Research Interest
Podoplanin, CLEC-2, PA tag, IDH1/2, CasMab, cancer-specific monoclonal antibody, glycobiology, development of therapeutic devices, monoclonal antibody, antibody-engineering
Publications
-
Mishima, K., Kato, Y., Kaneko, M. K., Nishikawa, R., Hirose, T., & Matsutani, M. (2006). Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta neuropathologica, 111(5), 483.
-
Kato, Y., Fujita, N., Kunita, A., Sato, S., Kaneko, M., Osawa, M., & Tsuruo, T. (2003). Molecular identification of Aggrus/T1α as a platelet aggregation-inducing factor expressed in colorectal tumors. Journal of Biological Chemistry, 278(51), 51599-51605.
-
Suzuki-Inoue, K., Kato, Y., Inoue, O., Kaneko, M. K., Mishima, K., Yatomi, Y., ... & Ozaki, Y. (2007). Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. Journal of Biological Chemistry, 282(36), 25993-26001.
